Key result
Both remifentanil and alfentanil significantly attenuated the maximum systolic arterial pressure increase following double-lumen endobronchial intubation compared to placebo (36±26 and 33±30 mmHg vs 83±35 mmHg, p<0.05).
Why the study?
Does remifentanil or alfentanil reduce cardiovascular pressor responses to double-lumen endobronchial intubation in elderly patients undergoing thoracic surgery?
RCT (n=60)
Double-blind
Randomized
No
Does remifentanil or alfentanil reduce cardiovascular pressor responses to double-lumen endobronchial intubation in elderly patients undergoing thoracic surgery?
Absolute Event Rate: 36% vs 83%
p-value: p=<0.05
Both remifentanil and alfentanil effectively attenuate the hypertensive and tachycardic responses to double-lumen endobronchial intubation in elderly patients, but their use is associated with a high incidence of hypotension.
Supports remifentanil or alfentanil to blunt pressor responses during double-lumen intubation in elderly thoracic patients; confirms efficacy with hypotension caution.
Background: This study examined the cardiovascular responses to double-lumen endobronchial intubation during rapid sequence induction of anesthesia, and compared the effect of remifentanil and alfentanil in a randomized, double-blind, placebo-controlled study in three groups of 20 elderly patients each.
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2007) conducted an RCT in Elective thoracic surgery requiring lung isolation (n=60). Remifentanil or Alfentanil vs. Saline (placebo) was evaluated on Maximum increase in systolic arterial pressure (SAP) from pre-intubation values (p=<0.05). Both remifentanil and alfentanil significantly attenuated the maximum systolic arterial pressure increase following double-lumen endobronchial intubation compared to placebo (36±26 and 33±30 mmHg vs 83±35 mmHg, p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: